NASDAQ · EXOZ

eXoZymes Inc.

$4.71 +$0.01 (+0.21%) 1D After hours

Key Metrics

$43.62M
Market cap
P/E · TTM
Revenue · TTM
−$9.67M
Net income
EPS · TTM $-1.16
Dividend yield
Free cash flow −$7.09M
Beta · 1Y 1.22
EBITDA · TTM −$9.49M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    From its Apr 10 high, the share price fell 60%.

    Peak close $11.70 on Apr 10; trough close $4.70 on Jul 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -60%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 18
    The stock moved +23.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 18
  • Apr 6
    The stock moved +15.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$43.62M
Enterprise value
Shares outstanding9.3M
52-wk range$4.66 – $18.40
Avg volume · 20D7.1K
Net cash
Book value / share$0.18
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About eXoZymes Inc.
IPO dateNov 13, 2024
Employees32

EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -161.9% · —

Financial Health

Current ratio1.32
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$507.59K

Cash Flow · TTM

Operating CF −$6.89M
Capex −$196.48K
Free cash flow −$7.09M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings